These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26318054)

  • 1. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
    Medapi B; Suryadevara P; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Eur J Med Chem; 2015 Oct; 103():1-16. PubMed ID: 26318054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
    Jeankumar VU; Renuka J; Santosh P; Soni V; Sridevi JP; Suryadevara P; Yogeeswari P; Sriram D
    Eur J Med Chem; 2013; 70():143-53. PubMed ID: 24148991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
    Reddy KI; Srihari K; Renuka J; Sree KS; Chuppala A; Jeankumar VU; Sridevi JP; Babu KS; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Dec; 22(23):6552-6563. PubMed ID: 25456076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
    Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
    Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling.
    Jeankumar VU; Reshma RS; Janupally R; Saxena S; Sridevi JP; Medapi B; Kulkarni P; Yogeeswari P; Sriram D
    Org Biomol Chem; 2015 Feb; 13(8):2423-31. PubMed ID: 25569565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
    Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors.
    Salve PS; Alegaon SG; Sriram D
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1859-1866. PubMed ID: 28274627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
    Medapi B; Renuka J; Saxena S; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 May; 23(9):2062-78. PubMed ID: 25801151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
    Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
    Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
    Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
    Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
    Chaudhari K; Surana S; Jain P; Patel HM
    Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.
    Kale RR; Kale MG; Waterson D; Raichurkar A; Hameed SP; Manjunatha MR; Kishore Reddy BK; Malolanarasimhan K; Shinde V; Koushik K; Jena LK; Menasinakai S; Humnabadkar V; Madhavapeddi P; Basavarajappa H; Sharma S; Nandishaiah R; Mahesh Kumar KN; Ganguly S; Ahuja V; Gaonkar S; Naveen Kumar CN; Ogg D; Boriack-Sjodin PA; Sambandamurthy VK; de Sousa SM; Ghorpade SR
    Bioorg Med Chem Lett; 2014 Feb; 24(3):870-9. PubMed ID: 24405701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
    Kale MG; Raichurkar A; P SH; Waterson D; McKinney D; Manjunatha MR; Kranthi U; Koushik K; Jena Lk; Shinde V; Rudrapatna S; Barde S; Humnabadkar V; Madhavapeddi P; Basavarajappa H; Ghosh A; Ramya VK; Guptha S; Sharma S; Vachaspati P; Kumar KN; Giridhar J; Reddy J; Panduga V; Ganguly S; Ahuja V; Gaonkar S; Kumar CN; Ogg D; Tucker JA; Boriack-Sjodin PA; de Sousa SM; Sambandamurthy VK; Ghorpade SR
    J Med Chem; 2013 Nov; 56(21):8834-48. PubMed ID: 24088190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis.
    Shirude PS; Madhavapeddi P; Tucker JA; Murugan K; Patil V; Basavarajappa H; Raichurkar AV; Humnabadkar V; Hussein S; Sharma S; Ramya VK; Narayan CB; Balganesh TS; Sambandamurthy VK
    ACS Chem Biol; 2013 Mar; 8(3):519-23. PubMed ID: 23268609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
    Jeankumar VU; Kotagiri S; Janupally R; Suryadevara P; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Feb; 23(3):588-601. PubMed ID: 25541204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations.
    Kamsri P; Punkvang A; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
    SAR QSAR Environ Res; 2019 Nov; 30(11):775-800. PubMed ID: 31607177
    [No Abstract]   [Full Text] [Related]  

  • 17. Ligand-Based Virtual Screening for Discovery of Indole Derivatives as Potent DNA Gyrase ATPase Inhibitors Active against
    Pakamwong B; Thongdee P; Kamsri B; Phusi N; Taveepanich S; Chayajarus K; Kamsri P; Punkvang A; Hannongbua S; Sangswan J; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Leanpolchareanchai J; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2024 Aug; 64(15):5991-6002. PubMed ID: 38993154
    [No Abstract]   [Full Text] [Related]  

  • 18. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.
    Sriram D; Aubry A; Yogeeswari P; Fisher LM
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2982-5. PubMed ID: 16554151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gyrase ATPase domain as an antitubercular drug discovery platform: structure-based design and lead optimization of nitrothiazolyl carboxamide analogues.
    Jeankumar VU; Renuka J; Kotagiri S; Saxena S; Kakan SS; Sridevi JP; Yellanki S; Kulkarni P; Yogeeswari P; Sriram D
    ChemMedChem; 2014 Aug; 9(8):1850-9. PubMed ID: 24962352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads.
    Jeankumar VU; Renuka J; Pulla VK; Soni V; Sridevi JP; Suryadevara P; Shravan M; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Int J Antimicrob Agents; 2014 Mar; 43(3):269-78. PubMed ID: 24434114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.